Chicago-based Tempus has closed a $200 million Series F financing at a valuation of $3.1 billion.
Investors include Baillie Gifford, Franklin Templeton, New Enterprise Associates, Novo Holdings, Revolution Growth, and funds and accounts managed by T. Rowe Price. As part of the round, Robert Ghenchev from Novo Holdings will be joining Tempus’s board of directors.
The additional funds will be used to further enhance operations and accelerate expansion into new therapeutic areas and geographies. With this latest round, Tempus has raised $520 million since its founding in September 2015.
Given recent growth, the Tempus platform now touches more than 1 in 4 cancer patients in the United States. The technology is company advancing precision medicine through the collection and analysis of molecular and clinical data.
“From our founding, Tempus has been singularly focused on improving the lives of patients diagnosed with disease, starting with cancer,” Tempus Founder and CEO Eric Lefkofsky said in a statement. “Three and a half years later, we are empowering stakeholders across healthcare with insights derived from real-world clinical evidence connected to rich molecular data. We are humbled by the industry response thus far and remain committed to delivering on the promise of precision medicine to improve patient care.”
Tempus is in partnership with leading academic medical centers, National Cancer Institute-designated cancer centers, hospital networks, physicians, researchers and CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology.
With the largest connected clinical and genomic database aggregated from academic medical centers and community-based hospitals, the Tempus platform serves the entire healthcare ecosystem of providers, payers, researchers and life sciences companies. Using advanced machine learning, next-generation sequencing, and AI-assisted image recognition, the company’s platform accelerates discovery of new insights and enables physicians to make real-time, data driven decisions based upon those insights on behalf of their patients.
